Novel treatments against migraine are an urgent medical requirement. The a6 subunit-containing GABA A receptors (a6GABA A Rs) are expressed in trigeminal ganglia (TG), the hub of the trigeminal vascular system (TGVS) that is involved in the pathogenesis of migraine. Here we reveal an unprecedented role of a6GABA A Rs in ameliorating TGVS activation using several pharmacological approaches in an animal model mimicking pathological changes in migraine. TGVS activation was induced by intra-cisternal (i.c.) instillation of capsaicin in Wistar rats. Centrally, i.c. capsaicin activated the trigeminal cervical complex (TCC) measured by the increased number of c-Fos-immunoreactive (c-Fos-ir) TCC neurons. Peripherally, it elevated calcitonin gene-related peptide immunoreactivity (CGRP-ir) in TG and depleted CGRP-ir in the dura mater. Pharmacological approaches included a recently identified a6GABA A R-selective positive allosteric modulator (PAM), the pyrazoloquinolinone Compound 6, two a6GABA A R-active PAMs (Ro15-4513 and loreclezole), an a6GABA A R-inactive benzodiazepine (diazepam), an a6GABA A R-selective antagonist (furosemide), and a clinically effective antimigraine agent (topiramate). We examined effects of these compounds on both central and peripheral TGVS responses induced by i.c. capsaicin. Compound 6 (3e10 mg/kg, i.p.) significantly attenuated the TCC neuronal activation and TG CGRP-ir elevation, and dural CGRP depletion induced by capsaicin. All these effects of Compound 6 were mimicked by topiramate, Ro15-4513 and loreclezole, but not by diazepam. The brain-impermeable furosemide antagonized the peripheral, but not central, effects of Compound 6. These results suggest that the a6GABA A R in TG is a novel drug target for TGVS activation and that a6GABA A R-selective PAMs have the potential to be developed as a novel pharmacotherapy for migraine.
Diazepam is a classical benzodiazepine exerting its anxiolytic, sedative, antiepileptic and muscle relaxant activities by acting as a positive allosteric modulator (PAM) of abgGABA A Rs containing a1, a2, a3 or a5 subunits (Rudolph and Knoflach, 2011) . The diazepaminsensitive a6 subunit-containing GABA A receptors (a6GABA A Rs), however, have been much less investigated due to a lack of a highly selective pharmacological ligand. Recently, we have identified several pyrazoloquinolinones Varagic et al., 2013a Varagic et al., , 2013b and their deuterated derivatives as PAMs highly selective for GABA A Rs consisting of a6b2/ 3g2 subunits, and displayed their lack of sedative, ataxic and cytotoxic effects in rodents . Particularly, Compound 6 (originally coded as PZ-II-029) Varagic et al., 2013a Varagic et al., , 2013b Zhang et al., 1995) , a highly selective a6GABA A R PAM, has recently been used to explore the functional role of cerebellar a6GABA A Rs in the regulation of sensorimotor gating in our previous study .
The a6GABA A Rs are mainly expressed in cerebellar granular cells (Gutierrez et al., 1996; Pirker et al., 2000) , but also in some sensory neurons (Gutierrez et al., 1996) including trigeminal ganglia (TG) (Puri et al., 2012) . Recently, it was demonstrated that the a6 subunit-expressing TG neurons project to the temporomandibular joint (TMJ) of rats (Puri et al., 2011) , and that rats with a 30% reduction of TG a6GABA A Rs showed hyperalgesia to TMJ inflammation (Puri et al., 2012) . This suggests that TG a6GABA A Rs are important for inhibiting primary sensory afferents in the trigeminal pathway, supporting previous evidence for the presence of functional GABA A Rs in TG (Hayasaki et al., 2006) .
In addition to TMJ disorders, TG are also involved in the pathogenesis of migraine. TG neurons receive the peripheral input from dural vessels via the ophthalmic branch of trigeminal sensory nerves and send central projections to the trigeminal cervical complex (TCC) (Scheme 1) that subsequently projects to higherorder pain centers (Bae et al., 2004; Goadsby, 2006) . The TCC includes the trigeminal nucleus caudalis (TNC) and the upper cervical spinal dorsal horn (C 1/2 ) (Shigenaga et al., 1988) . TG in combination with their peripherally innervated dural vessels and centrallyprojected TCC form the trigemino-vascular system (TGVS). TGVS activation via both peripheral and central sensitizations and releasing calcitonin gene related peptide (CGRP) (Goadsby et al., 1988) is considered an essential neuropathogenic mechanism of migraine (Scheme 1). Peripheral sensitization of the TGVS is attributed to neurogenic inflammation in the meninges, which is characterized by vasodilation due to CGRP released from dural sensory nerve terminals, plasma extravasation secondary to capillary leakage, edema, and mast cell degranulation (Ramachandran, 2018) . Central sensitization of the TGVS due to TNC activation is also involved in nociceptive processing and cerebrovascular regulation, and contributes to migraine (Lance et al., 1983) .
Capsaicin is an agonist of vanilloid 1 type of transient receptor potential channels (TRPV1) that are co-expressed with CGRP and substance P in small and medium sized unmyelinated TG neurons (Bae et al., 2004; Caterina and Julius, 2001 ). TRPV1 activation in TG causes the release of CGRP that induces vasodilation and neurogenic inflammation within the meninges in experimental animals, mimicking migraine (Meents et al., 2010) . Given the possibility that TG a6GABA A Rs might be involved in inhibiting primary sensory afferents of the trigeminal system (Puri et al., 2012) we hereby investigated whether a6GABA A R PAMs can counteract both peripheral and central effects of capsaicin given by intracisternal (i.c.) injection in rats, an established rat model of TGVS activation to mimic migraine (Cutrer et al., 1999; Cutrer and Moskowitz, 1996; Fan et al., 2012) .
In addition to the a6GABA A R-selective Compound 6, Ro 15-4513 (Hadingham et al., 1996) and loreclezole (Wafford et al., 1994) , two PAMs of GABA A Rs including, but not selective to, a6GABA A Rs, were used as positive controls. Besides, diazepam, an a6GABA A R-inactive PAM (Hevers and Luddens, 2002; Whittemore et al., 1996) , was used as a negative control. For comparison, we also examined the effects of topiramate, a clinical effective anti-migraine agent. Results obtained suggest that a positive modulation of a6GABA A Rs can ameliorate capsaicin-induced changes in the TGVS with an efficacy similar to topiramate, indicating that a6GABA A Rs are novel targets for the development of anti-migraine agents. Finally, we substantiated that the targeted a6GABA A Rs are located in TG by confirming that systemic administration of furosemide, an allosteric a6GABA A R antagonist that does not cross the blood-brain barrier (BBB) (Seelig et al., 1994) , is able to antagonize effects of Compound 6.
Materials and methods

Animals
All animal care and experimental protocols were approved by the Institution of Care and Use of Laboratory Animals of the College of Medicine of National Taiwan University. Male Wistar rats at 8e10 weeks (250e300 g) were used. They were housed in an animal room with a 12-h light/12-h dark cycle and free access to food and water.
Intra-cisternal instillation of capsaicin
The TGVS activation model induced by i.c. instillation of capsaicin is similar to our previous study (Fan et al., 2012) . Briefly, rats were anesthetized by chloral hydrate (400 and 100 mg/kg, i.p. for inducing and maintaining anesthesia, respectively) and catheterized with a catheter (PE-10, SIMS Portex Ltd, Hythe, UK) inserted 3 mm deep into the cisterna magna. Rats were then placed in a prone position for 5.5 h. The capsaicin solution (10 nmol, 100 ml) was instilled through the catheter into the cisterna magna over 1 min. The rats were then placed in a reverse Trendelenburg position (À30 ) for 30 min to facilitate capsaicin distribution within the subarachnoid space, which was followed by a prone position for another 90 min. Rats were pretreated with Compound 6 or its vehicle by i.p. (100 ml) injection 30 min before capsaicin instillation.
Furosemide (20 mg/kg, i.p.) (Agunu et al., 2005) or its vehicle was co-administered with Compound 6. For the sham group, 100 ml of the vehicle of capsaicin was administered by i.c. instillation.
Two hours after capsaicin instillation, the rat was euthanized by an overdose of chloral hydrate and then perfused via the ascending aorta with paraformaldehyde (4%) as described previously (Fan et al., 2012) for further immunostaining measurements.
Immunohistochemistry of c-Fos protein in TCC sections
The preparation of TCC sections and c-Fos immunohistochemistry were conducted as described previously (Fan et al., 2012) . Briefly, brainstem with attached cervical cord was serially sectioned (50 mm) using a cryostat (LEICA CM3050S, Nussloch, Germany) from 1 mm rostral to the obex to the C6 level of the spinal cord. The sections at þ0.6, À1.2, and À9 mm from the obex of the rat were collected and subjected to c-Fos immunohistochemical staining. The total number of c-Fos immunoreactive (c-Fos-ir) TCC neurons was estimated based on the formula derived previously (Fan et al., 2012) : 16(N1 þ N2)/2 þ 53(N2 þ N3)/2, where N1, N2, and N3 were the c-Fos-ir neuronal numbers measured at the level of 0.6, À1.2, and À9 mm from the obex, respectively.
Free-floating immunohistochemistry of c-Fos protein was conducted using the avidin-biotin method as described previously (Fan et al., 2012) with an anti-c-Fos rabbit polyclonal antibody (1:7000 dilution, Calbiochem, San Diego, CA, USA), biotinylated anti-rabbit IgG (1:200, Vector Labs, Burlingame, CA, USA), and horseradish peroxidase avidin D (1:500, Vector Labs, Burlingame, CA, USA). Immunoreactions were visualized using the DAB Reagent kit (KPL, Gaithersburg, MD, USA).
c-Fos-ir neurons, i.e., neurons with stained nuclei, were counted under a microscope (Olympus BX51, Essex, UK). Data were reviewed by an investigator who was blinded to the treatment groups.
TG slice sections and CGRP immunofluorescence quantification
From each rat, two TG preparations were dissected and then serially sectioned at 50 mm thickness using a microtome (LEICA RM2245, Nussloch, Germany). Nine TG sections were dissected from the central part of either the left or right ganglion of a rat. Then, every third section was sampled for CGRP immunofluorescence, i.e. the immunofluorescent data was taken from three TG sections from each rat.
TG sections were incubated in blocking solution (PBS containing 5% normal goat serum, 0.2% Triton X-100) for 1 h at room temperature. Sections were then incubated overnight at 4 C with the rabbit primary antibody against CGRP (1:200; EMD Millipore, Burlington, MA, USA) and left overnight at 4 C in fluoresceinconjugated goat anti-rabbit IgG (1:50; Vector Labs, Burlingame, CA, USA) secondary antibody solution. Sections were then placed on microscope slides and mounted with Aqua Poly/Mount (Polyscience Inc., Warrington, PA, USA). The sliced tissues were examined using an inverted light microscope (Zeiss Axio Observer. D1; Carl Zeiss, Jena, Germany). All analyses were calculated under a field of TG at 100X magnification by the software of Image J. The expression intensity of CGRP was calculated from the immunoreactivity that displayed as the optical density multiplies activated areas in each image.
Dura mater preparations and quantification of CGRP density by immunohistochemistry
The dura mater dissected from the cranial cavity of the rat was prepared for CGRP immunohistochemical staining as described previously (Fan et al., 2012) . In brief, identical areas in six similar locations of the dura for each animal were selected and examined under an inverted microscope (ZEISS Axio Observer.D1, Jena, Germany). For each animal, the total lengths of positive-stained segmented lines in the field (100X) were measured in pixels by the software of Image J.
Immunohistochemistry of CGRP was performed with the 2.6. Double immunofluorecent staining of CGRP and a6GABA A Rs in TG TG sections were prepared as described in Section 2.4. After incubation in donkey serum blocking solution for 1 h, sections were incubated overnight at 4 C with the goat primary antibody against CGRP (1:100; Cat: ab36001, Lot: GR3186077-10, Abcam, Cambridge, UK) followed by Alexa Fluor 594-conjugated donkey anti-goat secondary antibody (1:300; Cat: 705-585-147, Lot: 130926, Life Technologies, Carlsbad, CA, USA) at room temperature for 1 h. Next, sections were incubated with the rabbit primary antibody against the a6 subunit of GABA A Rs (1:100; Cat: ab92747, Lot: GR272612-5, Abcam, Cambridge, UK), whose specificity has been confirmed by negative data after blocking of the antibody by the immunizing peptide. (http://www.abcam.com/gaba-areceptor-alpha-6-antibody-ab92747.html#description_images_1) (Yang et al., 2016) . The secondary antibody used is Alexa Fluor 488-conjugated donkey anti-rabbit antibody (1:300; Cat: 406416, Lot: B243796, BioLegend, San Diego, CA, USA). The double stained sections were mounted on slides with ProLong Gold Antifade Mountant (Thermo Fischer Scientific, Waltham, MA, USA) and visualized under a confocal microscope (LSM 780; Carl Zeiss, Jena, Germany).
To confirm the specificity of the secondary antibody, we incubated TG preparations with the secondary antibody only. This resulted in no staining of the tissue section (Fig. S1A ). To further confirm the expression of a6GABA A Rs in TG, we repeated the immunohistochemical staining in TG preparations using another primary antibody against the a6 subunit of GABA A Rs (1:100; NB300-196, Lot: kn205, Novus Biologicals, Littleton, CO). Its specificity has been confirmed by an absence of staining of the a6 subunit in a6-knock-out mice, as indicated by the supplier (https:// www.novusbio.com/products/gaba-a-r-alpha-6-antibody_nb300-196).
Drugs
Capsaicin (Sigma Chemical, St. Louis, MO, USA) was dissolved in the vehicle containing 10% ethanol and 10% Tween 80, sonicated for 5 min, and then further diluted (1:100) in an artificial cerebrospinal fluid solution (aCSF) as a stock solution stored at 4 C. The aCSF consisted of the followings (in mm): 117 NaCl, 4.5 KCl, 2.5 CaCl 2 , 1.2 MgCl 2 , 1.2 NaH 2 PO 4 , 25 NaHCO 3 , and 11.4 dextrose bubbled with 95% O 2 /5% CO 2 , pH 7.4. Compound 6 was synthesized as reported previously (Varagic et al., 2013a) . Loreclezole, Ro15-4513, and diazepam (under the approval from Taiwan Food and Drug Administration, the Ministry of Health and Welfare, Taiwan) were purchased from Tocris Bioscience (Bristol, UK) and furosemide from Sigma-Aldrich (St. Louis, USA). All compounds were dissolved in a vehicle containing 20% DMSO, 20% Cremophor ® EL (polyoxyethylene castor, Sigma-Aldrich) and 60% normal saline.
Drug treatments and statistical analysis
Rats were randomly divided into 11 groups. Among them, ten groups received i.c. capsaicin instillation and one group received i.c. instillation of the vehicle of capsaicin as the sham control group. Each one of the ten capsaicin-treated groups was treated differently; being pretreated with 1, 3, or 10 mg/kg (i.p.) of Compound 6 or its vehicle, or with topiramate, loreclezole, Ro 154513, diazepam, or 3 mg/kg Compound 6 with and without furosemide, respectively, at 30 min before capsaicin instillation.
All statistical analyses were performed with IBM SPSS Statistics 20 for Windows. Data were expressed as mean ± S.E. Differences among groups were compared using the Kruskal-Wallis test. Then, differences between the tested group versus the capsaicin-treated group (Family-1, Table S1 ) or versus the sham-control group (Family-2, Table S2 ) were compared using the Mann-Whitney U test followed by the BenjaminieHochberg correction (BHC), which was used to control the false positive rate due to multiple comparisons (McDonald, 2014) . The p value of each comparing pair in a family was ranked. The difference was considered statistically significant when a p value < BHC value, which is the p value multiplied by i/m; m is the total number of comparisons in each family, and i is the rank of the p value in the family. The n numbers are the numbers of rats tested in each treatment group. From each rat, TCC, TG and dura tissue samples were prepared.
Results
As reported previously Fan et al., 2012) , i.c. capsaicin (10 nmol) instillation in rats significantly activated the TGVS in both central and peripheral sites. Centrally, it induced neuronal activation in the TCC, which can be measured by the increased number of c-Fos-ir TCC neurons (Fig. 1A , Cap vs. Sham). In the periphery, capsaicin led to increased CGRP-ir in TG ( Fig. 2A , Cap vs. Sham) and CGRP release from TG peripheral terminals as indicated by the depletion of CGRP-ir in the dura mater (Fig. 3A , Cap vs. Sham). Fig. 1B shows the total number of c-Fos-ir TCC neurons in the groups of rats that received i.c. instillation of capsaicin with various pre-treatments as well as the sham control group that received i.c. instillation of the vehicle of capsaicine only. The differences among groups were significant (p < 0.001, Kruskal-Wallis test). The MannWhitney U test followed by the BenjaminieHochberg correction was used to compare each treatment group with the capsaicin group (Family 1, Table S1 ) or with the sham group (Family 2, Table S2 ). In total, 10 comparisons in each family have been conducted.
Compound 6 attenuated capsaicin-induced TCC neuronal activation
The number of c-Fos-ir TCC neurons was significantly increased in rats receiving capsaicin instillation, compared to the sham group (p ¼ 0.004, Table S2 , Sham vs. Vehicle-Cap, Fig. 1B ), as reported in our previous study (Fan et al., 2012) . In rats pretreated with Compound 6, the number of capsaicin-induced c-Fos-ir TCC neurons was decreased significantly at the dose of 3 (p ¼ 0.006, Fig. 1A , C3 vs. Vehicle-Cap) and 10 (p ¼ 0.003, Fig. 1A , C10 vs. Vehicle-Cap) mg/ kg, but not 1 mg/kg (p > 0.05, Fig. 1A , C1 vs. Vehicle-Cap), compared to the vehicle-pretreated capsaicin group (Fig. 1A and B, Table S1 ).
but not by the a6GABA A R-inactive diazepam. The inhibitory effect of Compound 6 in the TCC was not significantly reversed by furosemide, a highly selective allosteric inhibitor for a 6 GABA A Rs. Scale bar: 500 mm (a); 100 mm (b). CC: central canal; Sp5C: spinal trigeminal nucleus caudalis. Data are mean ± SE. The n number shown in parentheses is the number of tested rats. *p < 0.005* i, vs. the Vehicle (Capsaicin) group; # p < 0.005* i, vs. the Sham group; i: the rank of p value (Tables S1 and S2 ). (Kruskal-Wallis test followed by post hoc Mann-Whitney U test with BenjaminieHochberg correction). Table S2 ).
Topiramate, a clinically effective anti-migraine agent, also attenuated capsaicin-induced TCC neuronal activation (p ¼ 0.011, Fig. 1A and B, TPM vs. Vehicle-Cap), at an effective dose (30 mg/kg, i.p.) reported previously in another migraine model (Andreou and Fig. 3 . Effects of Compound 6, topiramate, loreclezole, Ro 15-4513, or diazepam on capsaicin-induced neuronal activation and anti-a6GABA A R effects of furosemide in the dura mater. Immunohistograms (A) and the average of total length of CGRP-ir nerve fibers (B) in the dura mater of rats in i.c. capsaicin-treated group with various pretreatments as in Fig. 1 , as well as in Sham group (a, b) . Note that Compound 6 at 3 or 10, but not 1, mg/kg significantly suppressed capsaicin-induced depletion of dura CGRP-ir in a manner comparable to topiramate. The capsaicin-induced CGRP depletion inhibited by Compound 6 at 3 mg/kg is significantly reversed by furosemide. Loreclezole and Ro 15-4513 significantly inhibit capsaicin induced CGRP depletion in the dura, but diazepam does not. Scale bar: 1000 mm (a), 400 (b) and 100 mm (c). The length of CGRP-ir nerve fibers (arrowhead), stained by immunohistochemistry, in the dura mater was quantified by Image J. The total length of CGRP-ir fibers (in pixel) in six fixed comparable areas of the dura mater in each rat was collected. Filled arrowhead: CGRP-ir nerve fiber; Empty arrowhead: dural vessel. Data presentation and statistical analyses are the same as in Fig. 1 . Goadsby, 2011) . Interestingly, topiramate reduced the activated TCC neuronal number to a level that is still higher than in the sham group (p ¼ 0.011, Fig. 1A and B, TPM vs. Sham). Therefore, topiramate, like Compound 6, did not completely abolish i.c. capsaicininduced TCC neuronal activation. Fig. 2 shows the CGRP-ir in TG of rats in various groups as in Fig. 1 . The differences among groups were significant (p < 0.001, Kruskal-Wallis test). The Mann-Whitney U test followed by the BenjaminieHochberg correction shows that the CGRP-ir in TG in the capsaicin-treated group was significantly higher than in the sham group (p ¼ 0.006, Fig. 2A and B, Vehicle-Cap vs. Sham), as reported in our previous study (Fan et al., 2012) . Compound 6 dosedependently reduced capsaicin-induced elevation of CGRP-ir in TG (Fig. 2B) . The TG CGRP-ir was significantly suppressed by Compound 6 at the dose of 3 (p ¼ 0.018, Fig. 2A, C3 vs. Vehicle-Cap) and 10 mg/kg (p ¼ 0.004, Fig. 2A, C10 vs. Vehicle-Cap), but not 1 mg/kg (p > 0.05, Fig. 2A, C1 vs. Vehicle-Cap), as compared to the vehiclecapsaicin group. The TG CGRP-ir level was suppressed to the level as in the sham group by 3 or 10 mg/kg of Compound 6 (3 and 10 mg/ kg Compound 6 vs. Sham, ¼ C3 vs. Sham and C10 vs. Sham, p ¼ 0.347 and 0.715, respectively; Fig. 2A and B, Table S2 ).
Compound 6 suppressed capsaicin-induced CGRP-ir in TG
Similarly, topiramate completely suppressed capsaicin-induced elevation of CGRP-ir in TG (p ¼ 0.011, Fig. 2A and B, TPM vs. Vehicle-Cap). The CGRP-ir in the topiramate-pretreated group was significantly reduced to the level of the sham group (p ¼ 0.142, Fig. 2A and B, TPM vs. Sham).
3.3. Compound 6 rescued capsaicin-induced depletion of CGRP-ir in the dura mater Fig. 3 shows the CGRP-ir, quantified by the CGRP-ir nerve fiber length, in the dura mater of rats in various treatment groups as in Fig. 1 . The differences among groups were significant (p < 0.001, Kruskal-Wallis test). The Mann-Whitney U test followed by the BenjaminieHochberg correction shows that after i.c. capsaicin instillation, the CGRP-ir in the dura mater was significantly depleted (Fig. 3A and B, Vehicle-Cap vs. Sham) as reported previously (Fan et al., 2012) , which was demonstrated by the reduction of CGRP-ir nerve fiber length in the dura mater of capsaicin-treated group (p ¼ 0.004, Fig Interestingly, topiramate also significantly rescued capsaicininduced CGRP depletion in the dura mater (p ¼ 0.011, Fig. 3A , TPM vs. Vehicle-Cap). However, there was still a significant difference between the TPM and the sham groups (p ¼ 0.011, Fig. 3A , TPM vs. Sham), suggesting only a partial recovery.
3.4. Loreclezole and Ro15-4513, two a6GABA A R-acting PAMs, mimicked effects of compound 6 in capsaicin-induced migraine model
Loreclezole is a PAM of GABA A Rs containing b2 or b3 subunits and any one of the six a subunits, including a6GABA A Rs (Wafford et al., 1994; Whittemore et al., 1996) acting through a binding site different from that for benzodiazepines (Wafford et al., 1994) . Loreclezole, at 40 mg/kg (i.p.) that was effective in increasing GABAergic sensitivity in an alcohol-intolerant rat model (Wong et al., 1996) , significantly reduced the number of capsaicinincreased c-Fos-ir TCC neurons (p ¼ 0.011, Fig. 1A and B, LCZ vs. Vehicle-Cap), prevented capsaicin-induced elevation of CGRP-ir in TG (p ¼ 0.011, Fig. 2A and B, LCZ vs. Vehicle-Cap), and significantly rescued capsaicin-induced depletion of dural CGRP-ir (p ¼ 0.011, Fig. 3A and B, LCZ vs. Vehicle-Cap).
Ro 15-4513 is an imidazobenzodiazepine acting as a PAM at the benzodiazepine binding site of a4-and a6-subunit-containing GABA A Rs but also as a negative allosteric modulator via the benzodiazepine site of a1-, a2-, a3-or a5-subunit-containing GABA A Rs (Hadingham et al., 1996; Whittemore et al., 1996; You et al., 2010) . Ro15-4513 at 5 mg/kg (i.p.) that effectively modulated the GABA A receptor activity in ethanol-treated rats (Kuzmin et al., 2012) , also significantly reduced the number of capsaicinincreased c-Fos-ir TCC neurons (p ¼ 0.01, Fig. 1A and B, Ro vs. Vehicle-Cap), prevented capsaicin-induced CGRP-ir in TG (p ¼ 0.011, Fig. 2A and B, Ro vs. Vehicle-Cap), and rescued capsaicininduced depletion of dural CGRP-ir (p ¼ 0.006, Fig. 3A and B, Ro vs. Vehicle-Cap). Interestingly, similar to Compound 6 and topiramate, neither loreclezole nor Ro 15-4513 was able to reduce the number of capsaicin-activated TCC neurons to the baseline level as measured in the sham group (Fig. 1B and 3B ).
Diazepam, an a6GABA A R-inactive benzodiazepine, did not affect capsaicin-induced central and peripheral responses in the TGVS
Diazepam is the prototype benzodiazepine that binds at the benzodiazepine binding site (at the interface of a-and g-subunits) of a1-, a2-, a3-, or a5-subunit-containing abgGABA A Rs, but is inactive at a4-or a6-subunit-containing GABA A Rs (Hevers and Luddens, 2002; Whittemore et al., 1996) . In contrast to loreclezole or Ro 15-4513, diazepam did not affect capsaicin-induced TGVS activation in both central and peripheral ends. It did not significantly affect the number of c-Fos-containing TCC neurons (p ¼ 0.273 Fig. 1A and B, DZ vs.Vehicle-Cap), the CGRP-ir in TG (p ¼ 0.522, Fig. 2A and B, DZ vs. Vehicle-Cap) or the CGRP-ir in the dura mater (p ¼ 0.136, Fig. 3A and B, DZ vs. Vehicle-Cap) induced by capsaicin instillation.
3.6. Furosemide (i.p.), an a6GABA A R antagonist, prevented the peripheral effects of Compound 6 in the capsaicin-induced migraine model
In addition to TG (Puri et al., 2011 (Puri et al., , 2012 that is located outside the BBB (Eftekhari et al., 2015) , the site of action of a6GABA A R PAMs may also be in other brain regions where a6GABA A Rs are located, such as cerebellar granular cells (Gutierrez et al., 1996; Pirker et al., 2000) , the cochlea nuclei (Drescher et al., 1993) , and the hippocampus (Yang et al., 2016 ), since all three tested a6GABA A R PAMs are BBB-permeable and were administered systemically. To further substantiate that Compound 6 targets a6GABA A Rs located in TG, we investigated whether systemic administration of a BBBimpermeable a6GABA A R antagonist would block the effects of Compound 6. Furosemide was used since it is BBB-impermeable (Seelig et al., 1994) and it is an a6GABA A R-selective antagonist that effectively blocked the effects of Compound 6, Ro 15-4513 and loreclezole in our previous study .
We examined effects of systemic-administered furosemide (20 mg/kg, i.p.) on Compound 6 (3 mg/kg, i.p.)-induced inhibition of TCC neuronal activation (Fig. 1A, C3þFuro) , TG CGRP-ir ( Fig. 2A,  C3þFuro ) and dural CGRP depletion (Fig. 3A, C3þFuro) induced by capsaicin. In the TCC, the c-fos-ir cell number in capsaicin-treated rat group pretreated with Compound 6 (3 mg/kg)þFurosemide was still significantly reduced (p ¼ 0.01, Fig. 1A , C3þFuro vs. Veh-Cap, Fig. 1B) , as observed in the group pretreated with Compound 6 (3 mg/kg) plus the vehicle of furosemide (p ¼ 006, Fig. 1A , C3þVeh vs. Veh-Cap, Fig. 1B ). This suggests that systemic administration of furosemide did not significantly affect Compound 6-induced inhibitory effect on TCC neuronal activation induced by capsaicin.
On the other hand, furosemide completely reversed Compound 6-induced inhibitory effects in TG. The CGRP density in TG in the Compound 6 (3 mg/kg)þFurosemide pre-treated group was significantly restored, as compared with the sham group (p ¼ 0.018, Fig. 2A, C3þFuro vs. Sham, Fig. 2B ) to level as in capsaicin-treated group (p ¼ 0.2; Fig. 2A, C3þFuro vs. Vehicle-Cap). This is unlike the significant reduction observed in the Compound 6 (3 mg/kg)þ Vehicle pretreated group (p ¼ 0.006; Fig. 2A , C3þVeh vs. VehicleCap). Therefore, furosemide completely reversed the inhibitory effect of Compound 6 in TG. Similarly, furosemide also completely reversed the enhancing effect of Compound 6 on CGRP release in the dura mater (p ¼ 0.15, Fig. 3B , C3þFuro vs. Vehicle-Cap, whereas, p ¼ 0.004, Fig. 3A , C3þFuro vs. Sham, Fig. 3B ).
The expression of a6GABA A Rs and CGRP in TG
To investigate a possible co-localization of a6GABA A Rs and CGRP, we conducted double staining of the a6 subunit of GABA A Rs (a6) and CGRP in TG sections prepared from capsaicin-treated rats. Fig. 4 demonstrates a section with double immunofluorescent staining of CGRP (red) and a6 (green) (Fig. 4AeC) , and the monochrome micrographs of CGRP (Fig. 4D) and a6 (Fig. 4E) , respectively, in a rat TG section. In agreement with the results in Fig. 2 , CGRP was densely stained in TG neurons of capsaicin-treated rats (Fig. 4D) .
Interestingly, a6 was also densely stained in TG neurons of capsaicin-treated rats (Fig. 4E) . A single-immunoreactive staining of a6 in another TG section (Fig. 4F ) also shows dense distribution of the a6 protein in capsaicin-treated rat TG. Although there were neurons immunoreactive only to a6 (green, filled arrowheads, Fig. 4C , E) or to CGRP (red, open arrowheads, Fig. 4C and D) , many TG neurons were double-immunoreactive to a6 and CGRP (Fig. 4C , yellow color, arrows). These results suggest that a6GABA A Rs are colocalized with CGRP in many TG neurons.
The dense expression of a6 in TG neurons of capsaicin-treated rats was further confirmed by a single immunofluorescent staining of a6 using a different primary antibody against the a6 subunit (NB300-196, Novus Biologicals). As shown in Fig. S1B , a6 was densely distributed in a TG section of capsaicin-treated rats with a similar distribution pattern as seen in Fig. 4F , where the a6 antibody (ab92747, Abcam, Cambridge, UK) was used for the double immunofluorecence.
4. Discussion 4.1. a6GABA A R PAMs ameliorate both peripheral and central responses in capsaicin-induced TGVS activation in a rat model mimicking migraine
In this study, we used a rat model mimicking pathological changes in migraine (Fan et al., 2012) induced by i.c. instillation of capsaicin. This migraine model has previously been employed for evaluating anti-migraine agents, including the clinically effective valproic acid and a sumatriptan analogue (Cutrer et al., 1999; Cutrer and Moskowitz, 1996) . It is in agreement with the peripheral CGRP hypothesis (Dodick et al., 2014; Sun et al., 2016) and the brain stem central sensitization hypothesis of migraine (Bae et al., 2004; Goadsby, 2006) , and displays both central and peripheral activation in the TGVS as we reported previously (Fan et al., 2012) .
Here, we found that Compound 6 attenuated capsaicin-induced elevation of TG CGRP-ir, TCC neuronal activation and depletion of dural CGRP-ir. Importantly, effects of Compound 6 in this migraine model were mimicked by two a6GABA A R-active PAMs, loreclezole and Ro 15-4513, but not by a6GABA A R-inactive diazepam. Compound 6 is a pyrazoloquinolinone and an a6GABA A R-selective PAM acting at the a6þb3-interface of GABA A Rs (Varagic et al., 2013a) . At concentrations up to 1 mM, it only enhanced GABA currents at a6b2/ 3g2GABA A Rs, but not at b2/3g2GABA A Rs containing a1-, a2-, a3-, a4-or a5-subunits (Varagic et al., 2013a) . Ro15-4513 is an imidazobenzodiazepine and a PAM at a4bg2GABA A Rs and a6bg2GA-BA A Rs but is also a negative allosteric modulator at a1-, a2-, a3-and a5-containing abgGABA A Rs by acting via the benzodiazepine binding site at the aþg-interface (Hadingham et al., 1996; Whittemore et al., 1996; You et al., 2010) . Loreclezole is a triazole derivative and a PAM at GABA A Rs containing b2 or b3 subunits (Wafford et al., 1994; Whittemore et al., 1996) . These three compounds not only have distinct structural backbones but also exhibit their effects via different modulatory mechanisms on various GABA A R subtypes. However, they all attenuated i.c. capsaicininduced peripheral and central effects in the rat TGVS. The only common feature is their PAM activity at a6GABA A Rs, which therefore may contribute to their effects in this migraine model. To the best of our knowledge, this is the first study providing evidence for the notion that a positive modulation of a6GABA A Rs can inhibit nociceptive activation of the TGVS.
Effects of Compound 6 are comparable to topiramate, a clinically effective antimigraine drug
Topiramate is known for its antiepileptic activity with several proposed targets of action, including Na þ channels, Ca 2þ channels, non-NMDA receptors and GABA A Rs (White, 2005) . Topiramate is also a clinically effective preventive treatment for migraine (Bussone et al., 2005) . In migraine animal models, topiramate can reduce superior sagittal sinus-evoked TCC neuronal firings (Storer and Goadsby, 2004) , attenuate neurogenic dural vasodilation likely through inhibiting prejunctional CGRP release (Akerman and Goadsby, 2005a) , and inhibit regional cerebral blood flow changes (Akerman and Goadsby, 2005b) . The mechanism(s) of its antimigraine activity are unclear but blocking peripheral GluR5 kainate receptors may contribute to its inhibition of neurogenic dural vasodilatation (Andreou et al., 2009 ). Interestingly, topiramate was also able to enhance GABA currents at several cloned GABA A Rs, including the one consisting of a6b3g2s subunits, when GABA was applied at low concentrations (0.1e1 mM) (Simeone et al., 2006) . It remains to be elucidated whether topiramate at the effective dose in this study can potentiate GABA-induced inhibition via a6b3g2s
GABA A receptors. The present findings that both peripheral and central effects of Compound 6 (3e10 mg/kg) are comparable to those of topiramate (30 mg/kg) suggest a potential clinical effectiveness of Compound 6 in the treatment of migraine.
The a6GABA A Rs mediating TGVS inhibition are probably located in TG
The fact that TG is located outside the BBB (Eftekhari et al., 2015) , and the finding that systemic furosemide, a BBBimpermeable a6GABA A R antagonist, prevented the effects of Compound 6 in the peripheral (TG and dura mater), but not in the central (TCC), sites of the TGVS, suggest that the targets of action of Compound 6 are a6GABA A Rs in TG. This conclusion is consistent with the recent notion that TG are important peripheral targeting sites for anti-migraine drugs. For example, botulinum toxin A (Aoki, 2005; Dodick et al., 2010) and several antibodies against CGRP or CGRP receptors (Bigal et al., 2015; Dodick et al., 2014; Sun et al., 2016; Tepper et al., 2017) , which are BBB-impermeable, are effective in the treatment of migraine.
In addition, several lines of evidence indicate that enhancing the GABA A R-mediated functions in TG may be an effective strategy for treating migraine. Valproic acid, a clinically used antimigraine agent that inhibits GABA degradation, can reduce capsaicininduced TNC activation as well as CGRP-and substance P-induced dural plasma protein extravasation (Lee et al., 1995; Meents et al., 2010) . The neuroactive steroid allopregnanolone (a progesterone metabolite), which is also a PAM of GABA A Rs, including a 6 GABA A Rs (Fodor et al., 2005) , was also effective in a similar migraine model (Cutrer and Moskowitz, 1996) . Effects of both valproic acid and allopregnanolone were attenuated by i.p. administration of the BBB-impermeable GABA A R antagonist, bicuculline methiodide, supporting the conclusion that both compounds exert their effects via GABA A Rs in TG.
4.4. The expression and possible functions of a 6 GABA A Rs in TG In TG, GABA is synthesized and released mainly by neurons, but is accumulated by their surrounding satellite cells (Hayasaki et al., 2006) . Cell bodies of mammalian sensory ganglia are generally devoid of synaptic contacts, but exogenous GABA can induce Cl À currents in all TG neurons examined (Hayasaki et al., 2006) . It was thus hypothesized that frequently firing sensory neurons can lead to elevated extracellular K þ concentrations during repolarization of neurons in between action potentials that might induce GABA release from satellite cells and/or neuronal cells, providing an inhibitory feedback to firing sensory neurons (Hayasaki et al., 2006) . Immunohistochemical studies in 2e3 week-old rats demonstrated that the majority of TG neurons express a1, a3, a4, a5, b2/3, and g1/2/3 subunits of GABA A Rs, while a6 and d subunits were detected only in a subset of small neurons. (Hayasaki et al., 2006) .
a6GABA A Rs might thus be partially expressed in the same small unmyelinated sensory neurons that contain TRPV1, CGRP, and substance P (Bae et al., 2004) . In addition, the extremely high GABA sensitivity of a6GABA A Rs make them ideally suited for becoming modulated by already small amounts of extracellular GABA (Karim et al., 2013; Mortensen et al., 2011) . On the other hand, in a subsequent immunofluorescent study performed in adult rats (Puri et al., 2012) , it was demonstrated that a6 was expressed not only in TG neurons but also in satellite cells. Moreover, the population of a6-positive neurons was quite high in this study and comprised up to 86%, 74% and 74% of small, medium and large TG neurons, respectively (Puri et al., 2012) . The difference in the age of rats investigated in these studies might have contributed to the different abundance of a6GABA A Rs observed.
TG neurons, however, are heterogeneous. While numerous small and medium sized neurons in TG stained for TRPV1, only 29% of these neurons co-stained for TRPV1, CGRP, and substance P, while 44% co-stained for TRPV1 and CGRP, and 54% stained for TRPV1 and neither CGRP nor substance P (Bae et al., 2004) . In another study, CGRP was identified in about 50% of all TG neurons (Reuss et al., 1992) . Together with the high percentage of a6GABA A Rs (~80%) in TG neurons (Puri et al., 2012) , these data suggest a partial coexpression of a6GABA A Rs with TRPV1 and CGRP.
An abundant expression of a6GABA A Rs in TG was also suggested in our study (Fig. 4) In the migraine model we employed, intra-cisternal capsaicin might have directly activated the TRPV1 channels, which are located at central terminals of TG neurons (Evans et al., 2012; Oxford, 2013 ) (Scheme 1). The resulting terminal depolarization and the subsequent firing of action potentials might have backpropagated to TG and the dura mater and released CGRP within the meninges, causing vasodilation, plasma extravasation, edema, mast cell degranulation and inflammation (Ramachandran, 2018) . Alternatively, capsaicin might have induced a noxious meningeal stimulation (Mitsikostas et al., 1998) possibly via activating TRPV1 channels in the sensory nerve terminals of the dura mater. The peripheral terminal depolarization might again have elicited action potentials and propagated to TG neurons. In any case, rapid firing of TG neurons would have caused an elevation of the extracellular K þ concentration, and a subsequent release of GABA from TG neurons and/or satellite cells (Minchin, 1975) . Subsequent activation of the highly GABA-sensitive a6GABA A Rs on the cell bodies of TG neurons would then have suppressed the firing of those TG neurons expressing a6GABA A Rs, and hence reduced CGRP release from peripheral terminals as well as synaptic transmission at central terminals of the trigeminal nucleus caudalis. Activation of the trigeminal nucleus caudalis contributes to the central sensitization of the TGVS and is involved in nociceptive processing and cerebrovascular regulation and thus also contributes to the symptoms of migraine (Lance et al., 1983) . The a6GABA A R-mediated reduction of this activation, and especially the enhancement of this reduction by a6GABA A R PAMs might thus have ameliorated the symptoms of migraine.
Such a tentative mechanism may explain the findings that all three a6GABA A R PAMs completely attenuated capsaicin-induced CGRP elevation in TG. However, a6GABA A R activation in TG neurons may not be able to inhibit the CGRP released from peripheral terminals that are activated by the locally released neuroinflammatory mediators. This may explain the observed incomplete inhibition of CGRP-release in the dura mater by a6GABA A R PAMs. In addition, capsaicin may also directly activate the TRPV1 channels on the TCC secondary neurons. This may explain the incomplete inhibition of capsaicin-induced c-Fos expression in TCC neurons by a6GABA A R PAMs.
Compound 6 seems to exert its effects via a6b2/3g2 receptors
The abundantly expressed a6 in TG observed in the present study as well as in Puri et al. (2012) and the findings that a6GABA A R-active PAMs but not the a6GABA A R-inactive diazepam can reduce capsaicin-induced TGVS activation suggest that the a6 subunits expressed in TG are incorporated into GABA A Rs. However, the subunit composition of a6GABA A Rs within TG neurons is currently unclear because both a6b2/3g2-and a6b2/3d-containing GABA A Rs might be present in these neurons. In the absence of synapses at cell bodies of TG neurons (Hayasaki et al., 2006) , all these receptors are located extrasynaptically. Compound 6 is a highly selective PAM of a6b2/3g2GABA A Rs (Varagic et al., 2013a (Varagic et al., , 2013b although it also modulated a6b2/3dGABA A Rs at high concentrations . In contrast, Ro 15-4513 is an antagonist of a6b2/3dGABA A Rs Wallner et al., 2014) , although being a PAM at a6b3g2GABA A Rs (Adkins et al., 2001; Suzdak et al., 1986; Wallner et al., 2006) . It is unlikely that Ro15-4513 exerts its anti-capsaicin effect via modulating a6b3dGABA A Rs. Therefore, Compound 6 as well as Ro15-4513 may exert their anti-capsaicin effects via modulating a6b2/3g2GABA A Rs.
Limitations of the study
The present study for the first time demonstrates that a6GABA A R-selective PAMs significantly attenuated both central and peripheral responses of TGVS in a rat model of migraine induced by i.c. instillation of capsaicin. This in vivo model is a useful tool to study the histopathological changes in migraine-associated areas such as TG, TCC and dura mater, and has been employed to evaluate the pharmacological potency of various anti-migraine agents, including clinically effective valproic acid and a sumatriptan analogue (Cutrer et al., 1999; Cutrer and Moskowitz, 1996) . However, there are some limitations to the present model. First, capsaicin was administered intracisternally but not directly on the dura mater. The TCC neurons that may be directly activated likely include those not innervated by TG. This may explain that even topiramate, a clinically-effective antimigraine agent, was unable to completely abolish the TCC neuronal activation. Nevertheless, both a6-GABA A R PAMs and topiramate effectively inhibited peripheral responses in the TGVS which represent a hallmark of migraine neuropathogenesis (Pietrobon and Striessnig, 2003) . Second, all GABA A R PAMs were administered before i.c. instillation of capsaicin, supporting a future clinical applications as a preventive treatment for migraine. This notion is also in agreement with the effectiveness of topiramate, which is used clinically for a preventive, but not abortive, treatment for migraine. It remains to be further elucidated whether GABA A R PAMs can be used as abortive treatments. Third, in the present study the animals were under anesthesia throughout the study protocol. Further studies will have to be conducted to examine the effects of a6GABA A R-selective PAMs in migraine-associated behaviors such as allodynia, facial grimace and photophobia (Harris et al., 2017) .
Future prospects
Novel treatments of migraine remain an unmet medical need since more than 20% migraineurs are refractory to current antimigraine medications or intolerant to their side effects (TfeltHansen, 2006) . Migraine is one of the leading causes of disability with a prevalence of 12e15% (Lipton et al., 2001 ). Our results suggest that a6GABA A R-selective PAMs are potential novel antimigraine agents. The limited regional distribution of a6GABA A Rs and the absence of modulation of diazepam-sensitive GABA A Rs by Compound 6 Knutson et al., 2018; Varagic et al., 2013a) suggest that a6GABA A R-selective PAMs might have fewer side effects than current antimigraine agents. Since the non-BBB protected TG seems to be the site of the anti-migraine action of Compound 6, BBB-impermeable a6GABA A R PAMs may also have the potential to be novel anti-migraine agents. Their development thus represents another strategy for a migraine therapy with even less side effects.
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